Theriva Biologics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 30, 2023. The company is a clinical-stage biopharmaceutical business with no approved products or meaningful product revenue. Following its March 2022 acquisition of VCN Biosciences, it shifted strategic focus toward oncology and VCN-01, an oncolytic adenovirus. The filing also presents audited 2021 comparatives.
Financial performance and position
| Metric | FY2022 / December 31, 2022 | FY2021 / December 31, 2021 |
|---|---|---|
| Revenue | No meaningful revenue reported | No meaningful revenue reported |
| Research and development expense | $11.7 million | $7.8 million |
| General and administrative expense | $9.9 million | $6.5 million |
| Operating loss | $21.6 million | $14.3 million |
| Net loss | $19.7 million; $1.31 per share | $14.3 million; $1.90 per share |
| Net loss attributable to common stockholders | $20.0 million, including a $0.34 million warrant-related deemed dividend | $23.2 million, including preferred-stock dividends and deemed dividends |
| Cash and cash equivalents | $41.8 million | $67.3 million |
| Cash used in operating activities | $19.1 million | $12.9 million |
| Total assets / liabilities | $71.9 million / $17.3 million | $70.4 million / $5.0 million |
| Debt | $0.28 million of acquired Spanish government loans; maturities 2023–2028 | No debt shown |
Gross margin is not applicable because the filing reports no meaningful product revenue. The $1.4 million income tax benefit in 2022 was primarily related to VCN. The company had an accumulated deficit of approximately $291 million. Current assets were $45.5 million against current liabilities of $7.1 million.
Material changes and significant items
- R&D expense rose approximately 50%, primarily reflecting VCN-01 clinical development; G&A expense rose approximately 51%, including acquisition-related operations, added personnel and contingent-consideration fair-value expense.
- Cash declined by $25.5 million year over year. 2022 financing included approximately $2.7 million net proceeds from Series C and D preferred stock; the company reported no ATM common-stock sales in 2022. In 2021, ATM sales generated approximately $66.0 million and warrant exercises approximately $8.0 million.
- The VCN acquisition closed March 10, 2022. Consideration was valued at approximately $22.8 million, including $4.7 million cash, $6.6 million of common stock and $11.1 million initial fair value of contingent consideration. The company also assumed approximately $2.4 million of liabilities and committed to a roughly $27.8 million three-year development and operating budget for VCN.
- The company paid Grifols a $3.0 million VCN milestone in Q4 after FDA clearance to proceed with a Phase 2 VCN-01 pancreatic cancer trial. The acquisition agreement includes up to $70.2 million in additional milestone consideration; $10.2 million was recorded as contingent consideration at year-end.
- In December, the company repurchased 720,000 shares for $288,072, held as treasury stock. A 1-for-10 reverse stock split took effect in July; the company changed its name and ticker from Synthetic Biologics/SYN to Theriva Biologics/TOVX in October.
Outlook, risks and unusual matters
- Management estimated cash would fund operations through the second quarter and into the third quarter of 2024, including ongoing early-stage programs and committed VCN obligations. The company stated that completing later-stage trials will require additional financing or a significant partnership; no committed funding source was disclosed.
- VIRAGE, a randomized Phase 2b trial of VCN-01 plus standard chemotherapy for metastatic pancreatic cancer, began dosing its first patients in January 2023. The filing expected enrollment of 92 patients. First dosing occurred after the fiscal year-end.
- Management is exploring partnering or out-licensing SYN-004 and SYN-020 following the strategic shift to oncology. SYN-004’s proposed Phase 3 CDI-prevention program was estimated to cost more than $80 million and is not expected to proceed without a partner. SYN-020 had favorable Phase 1 safety findings, but further development and partnering remain uncertain.
- The company restated its previously issued June and September 2022 interim financial statements after identifying an omitted VCN deferred tax asset and related tax benefit. The restatement reduced interim net losses by $0.5 million for the first half and $0.9 million for the first nine months; additional immaterial adjustments affected acquisition valuations. Investors are directed to rely on the restated information in this 10-K, not the previously filed interim reports.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because of material weaknesses involving non-routine transactions and tax accounting, IT access and change controls, and documentation of control performance. The auditor gave an unqualified opinion on the financial statements but did not express an opinion on internal-control effectiveness. VCN controls were excluded from management’s assessment while integration continued.
- Key risks include continued losses and cash burn, reliance on additional capital that could dilute shareholders, clinical and regulatory uncertainty, dependence on third-party manufacturers and trial providers, possible supply constraints, and NYSE American listing compliance. The filing reports no material pending legal proceedings and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Cash runway assumptions and the timing, amount and terms of any financing or partnership needed to complete VCN-01 trials.
- VIRAGE enrollment, trial milestones and whether clinical results support further development; distinguish early or small-study findings from confirmatory evidence.
- Potential cash obligations to Grifols, including milestone triggers, the recorded contingent-consideration balance and the committed VCN budget.
- Progress in remediating the material weaknesses and whether future filings report effective controls, including controls at the Spanish subsidiary.
- Restated interim figures and the assumptions underlying acquisition-related IPR&D, goodwill and contingent-consideration valuations.
- Potential dilution from convertible preferred stock, warrants, options, equity plans and future capital raises.